PALO ALTO, Calif., June 26, 2014 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company") today announced that it has completed the patient enrollment required for its Phase IIb trial to further evaluate the safety and efficacy of their proprietary adipose-derived mesenchymal precursor cell (haMPC)-based therapy ReJoinTM for Knee Osteoarthritis (KOA).
"We are pleased to reach this Company milestone and exceed enrollment of the forty-eight patients required for our Phase IIb clinical trial for Knee Osteoarthritis," said Dr. Cheng Xiang (Chase) Dai, VP and GM of Autologous Products Business Unit.
The Phase I/IIa clinical trial for this therapy was completed in Q4 2013, with the six-month follow-up data analysis concluding that ReJoinTM cell therapy for KOA patients is safe and revealing an increase in cartilage volume as early as three months after the therapy. (click here to view detailed six-month data)
About the Clinical Trial
The Phase IIb clinical research trial for KOA, registered with the U.S. National Institutes of Health (NIH) under the number NCT02162693 (click here to view), is led by Shanghai Renji Hospital, one of the largest teaching hospitals in China. The multi-center study has enrolled 53 patients to participate in a randomized, single blind trial.
The primary endpoints for this trial are knee-related pain, stiffness and function as measured using the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index questionnaire. The secondary endpoints are cartilage repair at six months by assessment of changes of the knee joint cartilage's volume measured with quantitative magnetic resonance imaging (MRI), in addition to NRS-11, SF-36 and KSCRS scores, and the recording of any moderate to serious adverse events.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
CONTACT: Sarah Kelly Director of Corporate Communications, CBMG +1 650 566-5064 email@example.com Vivian Chen Managing Director Investor Relations, Grayling +1 646 284-9427 firstname.lastname@example.org
Source:Cellular Biomedicine Group Inc.